| Diverse p120RasGAP interactions with doubly phosphorylated partners EphB4, p190RhoGAP, and Dok1. | Diverse p120RasGAP interactions with doubly phosphorylated partners EphB4, p190RhoGAP, and Dok1.
Vish KJ, Stiegler AL, Boggon TJ., Free PMC Article | 11/1/2023 |
| Docking protein 1 and free fatty acids are associated with insulin resistance in patients with type 2 diabetes mellitus. | Docking protein 1 and free fatty acids are associated with insulin resistance in patients with type 2 diabetes mellitus.
Ha X, Cai X, Cao H, Li J, Yang B, Jiang R, Li X, Li B, Xin Y., Free PMC Article | 11/22/2021 |
| Analysis of the DOK1 gene in breast cancer. | Analysis of the DOK1 gene in breast cancer.
Tuna E, Ersoy YE, Bulut P, Ozdemir F, Buyru N. | 10/24/2020 |
| Nck adapter proteins promote podosome biogenesis facilitating extracellular matrix degradation and cancer invasion. | Nck adapter proteins promote podosome biogenesis facilitating extracellular matrix degradation and cancer invasion.
Chaki SP, Barhoumi R, Rivera GM., Free PMC Article | 09/26/2020 |
| Decreased DOK1/2 expressions associated with their promoter hypermethylations predict adverse prognosis in AML. | Methylation-associated DOK1 and DOK2 down-regulation: Potential biomarkers for predicting adverse prognosis in acute myeloid leukemia.
He PF, Xu ZJ, Zhou JD, Li XX, Zhang W, Wu DH, Zhang ZH, Lian XY, Yao XY, Deng ZQ, Lin J, Qian J. | 09/21/2019 |
| Taken together, these results indicate that ATRA-enhanced expression of DOK1 activates PPARgamma leading to inhibition of cell proliferation and enhancement of cell apoptosis in MCF-7 cell. | DOK1/PPARgamma pathway mediates anti-tumor ability of all-trans retinoic acid in breast cancer MCF-7 cells.
Ding X, Wang W, Wang M, Wu J, Yao F. | 06/24/2017 |
| DOK1 was identified as a prognostic factor for non-metastatic CRC, and, via its drugability by PPARgamma-agonist, may constitute a potential target for future cancer treatments. | Subcellular compartmentalization of docking protein-1 contributes to progression in colorectal cancer.
Friedrich T, Söhn M, Gutting T, Janssen KP, Behrens HM, Röcken C, Ebert MPA, Burgermeister E., Free PMC Article | 02/18/2017 |
| DOK3 expression was not altered much in HTLV-1-infected T cells. | Expression of DOK1, 2, and 3 genes in HTLV-1-infected T cells.
Ohsugi T, Wakamiya M, Morikawa S, Fujita M. | 09/24/2016 |
| Results indicate that hypermethylation of tumor suppressor protein RASSF1A and docking protein 1 (DOK1) contributes to hepatocarcinogenesis and is associated to clinicopathological characteristics. | RASSF1A and DOK1 Promoter Methylation Levels in Hepatocellular Carcinoma, Cirrhotic and Non-Cirrhotic Liver, and Correlation with Liver Cancer in Brazilian Patients.
Araújo OC, Rosa AS, Fernandes A, Niel C, Villela-Nogueira CA, Pannain V, Araujo NM., Free PMC Article | 09/3/2016 |
| Data show that residues Ser745 and Ser756 in the integrin beta2 tail, which are adjacent to the NxxF motif, are required for docking protein 1, docking protein 1, 62kDa (downstream of tyrosine kinase 1) (Dok1) interaction. | An Alternative Phosphorylation Switch in Integrin β2 (CD18) Tail for Dok1 Binding.
Gupta S, Chit JC, Feng C, Bhunia A, Tan SM, Bhattacharjya S., Free PMC Article | 06/28/2016 |
| results support a model in which Dok1 phosphorylation normally suppresses localized Ras pathway activity in Crk-transformed cells via recruitment and/or activation of RasGAP | Phosphorylation of Dok1 by Abl family kinases inhibits CrkI transforming activity.
Ng KY, Yin T, Machida K, Wu YI, Mayer BJ., Free PMC Article | 08/1/2015 |
| Data implicate existence of alternate conformational states around the ligand binding pocket of the PTB domain of phosphoprotien Dok1 either in the native or in the near native conditions. | NMR characterization of the near native and unfolded states of the PTB domain of Dok1: alternate conformations and residual clusters.
Gupta S, Bhattacharjya S., Free PMC Article | 06/27/2015 |
| Deregulation of DOK1 gene expression by EBV and novel insights into the regulation of the DOK1 tumor suppressor in viral-related carcinogenesis. | Epstein-Barr virus down-regulates tumor suppressor DOK1 expression.
Siouda M, Frecha C, Accardi R, Yue J, Cuenin C, Gruffat H, Manet E, Herceg Z, Sylla BS, Tommasino M., Free PMC Article | 06/20/2015 |
| point mutations in DOK1 and DOK2 genes are detected with low frequency in chronic myelomonocytic leukemia but may have consequences for the function of the DOK2 PTB domain | Mutational analysis of the DOK2 haploinsufficient tumor suppressor gene in chronic myelomonocytic leukemia (CMML).
Coppin E, Gelsi-Boyer V, Morelli X, Cervera N, Murati A, Pandolfi PP, Birnbaum D, Nunès JA. | 04/11/2015 |
| A crucial role for DOK1 in the regulation of PDGF-BB-mediated tumour cell motility through a p130Cas-Rap1 signalling pathway. | A crucial role for DOK1 in PDGF-BB-stimulated glioma cell invasion through p130Cas and Rap1 signalling.
Barrett A, Evans IM, Frolov A, Britton G, Pellet-Many C, Yamaji M, Mehta V, Bandopadhyay R, Li N, Brandner S, Zachary IC, Frankel P. | 01/31/2015 |
| Taken together, these results reveal that Dok1 and Dok2 proteins are involved in an intrinsic negative feedback loop downstream of natural killer-cell-activating receptors in mouse and human. | Dok1 and Dok2 proteins regulate natural killer cell development and function.
Celis-Gutierrez J, Boyron M, Walzer T, Pandolfi PP, Jonjić S, Olive D, Dalod M, Vivier E, Nunès JA., Free PMC Article | 11/8/2014 |
| BRK has a role in targeting Dok1 for ubiquitin-mediated proteasomal degradation and in promoting cell proliferation and migration | BRK targets Dok1 for ubiquitin-mediated proteasomal degradation to promote cell proliferation and migration.
Miah S, Goel RK, Dai C, Kalra N, Beaton-Brown E, Bagu ET, Bonham K, Lukong KE., Free PMC Article | 11/8/2014 |
| The unique N-terminal region of SRMS regulates enzymatic activity and phosphorylation of its novel substrate docking protein 1. | The unique N-terminal region of SRMS regulates enzymatic activity and phosphorylation of its novel substrate docking protein 1.
Goel RK, Miah S, Black K, Kalra N, Dai C, Lukong KE. | 10/26/2013 |
| DNA methylation of the DOK1 core promoter region found in head and neck cancer cell lines hampered the recruitment of E2F1 to the DOK1 promoter and compromised DOK1 expression. | Transcriptional regulation of the human tumor suppressor DOK1 by E2F1.
Siouda M, Yue J, Shukla R, Guillermier S, Herceg Z, Creveaux M, Accardi R, Tommasino M, Sylla BS., Free PMC Article | 01/26/2013 |
| Studies demonstrate DOK-1 regulates allergen-induced Th2 immune responses by selective stimulation and inhibition of STAT-4 and STAT-6 signaling pathways, respectively. | An essential regulatory role of downstream of kinase-1 in the ovalbumin-induced murine model of asthma.
Lee CM, Jung ID, Noh KT, Lee JS, Park JW, Heo DR, Park JH, Chang JH, Choi IW, Kim JS, Shin YK, Park SJ, Han MK, Lee CG, Cho WK, Park YM., Free PMC Article | 09/1/2012 |
| hypermethylation of DOK1 is a potentially critical event in human carcinogenesis. | Inactivation of the putative suppressor gene DOK1 by promoter hypermethylation in primary human cancers.
Saulnier A, Vaissière T, Yue J, Siouda M, Malfroy M, Accardi R, Creveaux M, Sebastian S, Shahzad N, Gheit T, Hussain I, Torrente M, Maffini FA, Calabrese L, Chiesa F, Cuenin C, Shukla R, Fathallah I, Matos E, Daudt A, Koifman S, Wünsch-Filho V, Menezes AM, Curado MP, Zaridze D, Boffetta P, Brennan P, Tommasino M, Herceg Z, Sylla BS., Free PMC Article | 05/12/2012 |
| These findings are suggestive for a possible tumor suppressor role of DOK1 in epithelial ovarian cancer. | Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer.
Mercier PL, Bachvarova M, Plante M, Gregoire J, Renaud MC, Ghani K, Têtu B, Bairati I, Bachvarov D., Free PMC Article | 04/21/2012 |
| Cav1 cooperated with the endogenous Ras/MAPK inhibitor docking protein 1 (Dok1) to promote the ligand-dependent transcriptional activity of PPARgamma and to inhibit cell proliferation | The Ras inhibitors caveolin-1 and docking protein 1 activate peroxisome proliferator-activated receptor γ through spatial relocalization at helix 7 of its ligand-binding domain.
Burgermeister E, Friedrich T, Hitkova I, Regel I, Einwächter H, Zimmermann W, Röcken C, Perren A, Wright MB, Schmid RM, Seger R, Ebert MP., Free PMC Article | 11/12/2011 |
| these data support a model in which proteasome- mediated degradation of Dok-1 is an important contributive step toward tumor development and/or progression driven by OTKs | Oncogenic tyrosine kinases target Dok-1 for ubiquitin-mediated proteasomal degradation to promote cell transformation.
Janas JA, Van Aelst L., Free PMC Article | 08/27/2011 |
| Dok1 negatively regulates Dok2-mediated CD200R signaling through the recruitment of CrkL. | Downstream of tyrosine kinase 1 and 2 play opposing roles in CD200 receptor signaling.
Mihrshahi R, Brown MH., Free PMC Article | 01/8/2011 |